Introduction of human apolipoprotein E4 “domain interaction” into mouse apolipoprotein E
暂无分享,去创建一个
Robert V Farese | R. Raffai | K. Weisgraber | K H Weisgraber | R V Farese | R L Raffai | L M Dong | L. Dong
[1] L. Curtiss,et al. Apolipoprotein E is a biologically active constituent of the normal immunoregulatory lipoprotein, LDL-In. , 1986, Journal of immunology.
[2] N. Maeda,et al. Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe*2. , 1998, The Journal of clinical investigation.
[3] A. Takeshita,et al. Altered cholesterol metabolism in human apolipoprotein E4 knock-in mice. , 2000, Human molecular genetics.
[4] N. Maeda,et al. Targeted Replacement of the Mouse Apolipoprotein E Gene with the Common Human APOE3 Allele Enhances Diet-induced Hypercholesterolemia and Atherosclerosis* , 1997, The Journal of Biological Chemistry.
[5] G. Getz,et al. Isoform-specific binding of apolipoprotein E to beta-amyloid. , 1994, The Journal of biological chemistry.
[6] D. Hui,et al. Apolipoprotein E Inhibits Platelet-derived Growth Factor-induced Vascular Smooth Muscle Cell Migration and Proliferation by Suppressing Signal Transduction and Preventing Cell Entry to G1 Phase* , 1998, The Journal of Biological Chemistry.
[7] Robert V Farese,et al. Knockout of the mouse apolipoprotein B gene results in embryonic lethality in homozygotes and protection against diet-induced hypercholesterolemia in heterozygotes. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[8] T. Braun,et al. Myf-5 Revisited Loss of Early Myotome Formation Does Not Lead to a Rib Phenotype in Homozygous Myf-5 Mutant Mice , 2000, Cell.
[9] A. D. Roses,et al. Association of apolipoprotein E allele €4 with late-onset familial and sporadic Alzheimer’s disease , 2006 .
[10] L. Mucke,et al. Dominant negative effects of apolipoprotein E4 revealed in transgenic models of neurodegenerative disease , 2000, Neuroscience.
[11] B. Hogan,et al. Altered wound healing in mice lacking a functional osteopontin gene (spp1). , 1998, The Journal of clinical investigation.
[12] R. Schutgens. The metabolic and molecular bases of inherited disease, seventh edition—3-volume set Edited by Charles R. Scriver, Arthur L. Beaudet, William S. Sly, and David Valle. New York, McGraw-Hill, 1995, $285.84 (xxxvi + 4605 pages and 93-page index), ISBN 0-07909-826-6 , 1995, Trends in Endocrinology & Metabolism.
[13] R. Mahley,et al. Human apolipoprotein E: the Alzheimer's disease connection , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[14] S. Young,et al. Dual mechanisms for the low plasma levels of truncated apolipoprotein B proteins in familial hypobetalipoproteinemia. Analysis of a new mouse model with a nonsense mutation in the Apob gene. , 1998, The Journal of clinical investigation.
[15] R. Saiki,et al. A general method of in vitro preparation and specific mutagenesis of DNA fragments: study of protein and DNA interactions. , 1988, Nucleic acids research.
[16] R. Mahley,et al. Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond. , 1999, Current opinion in lipidology.
[17] G. Martin,et al. An Fgf8 mutant allelic series generated by Cre- and Flp-mediated recombination , 1998, Nature Genetics.
[18] D. Smith,et al. Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase. , 1988, Gene.
[19] R. Mahley,et al. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. , 1988, Science.
[20] J. Borén,et al. Identification of the low density lipoprotein receptor-binding site in apolipoprotein B100 and the modulation of its binding activity by the carboxyl terminus in familial defective apo-B100. , 1998, The Journal of clinical investigation.
[21] C. Sing,et al. Apolipoprotein E polymorphism and atherosclerosis. , 1988, Arteriosclerosis.
[22] D. Agard,et al. Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms. , 1994 .
[23] K. Weisgraber,et al. Human Apolipoprotein E4 Domain Interaction , 1996, The Journal of Biological Chemistry.
[24] Matthias Orth,et al. Expression of Human Apolipoprotein E3 or E4 in the Brains ofApoe−/− Mice: Isoform-Specific Effects on Neurodegeneration , 1999, The Journal of Neuroscience.
[25] A. Hofman,et al. Apolipoprotein E epsilon4 and the risk of dementia with stroke. A population-based investigation. , 1997, JAMA.
[26] I. Tesseur,et al. Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice. , 2000, The American journal of pathology.
[27] P. Chomczyński,et al. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.
[28] K. Weisgraber. Apolipoprotein E distribution among human plasma lipoproteins: role of the cysteine-arginine interchange at residue 112. , 1990, Journal of lipid research.
[29] Masahiko Watanabe,et al. Apo E structure determines VLDL clearance and atherosclerosis risk in mice. , 1999, The Journal of clinical investigation.
[30] L. Bernier,et al. Apolipoprotein E and atherosclerosis: insight from animal and human studies. , 1999, Clinica chimica acta; international journal of clinical chemistry.
[31] K. Weisgraber. Apolipoprotein E: structure-function relationships. , 1994, Advances in protein chemistry.
[32] R. Gregg,et al. Abnormal in vivo metabolism of apolipoprotein E4 in humans. , 1986, The Journal of clinical investigation.
[33] K. Weisgraber,et al. Human apolipoprotein E3 in aqueous solution. II. Properties of the amino- and carboxyl-terminal domains. , 1988, The Journal of biological chemistry.
[34] L. Mucke,et al. Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: increased susceptibility of females. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[35] H. Kaffarnik,et al. Differential Distribution of Apolipoprotein E Isoforms in Human Plasma Lipoproteins , 1989, Arteriosclerosis.
[36] D. Graham,et al. Amyloid β‐Protein, APOE Genotype and Head Injury , 1996 .
[37] M. Reyland,et al. Suppression of cAMP-mediated signal transduction in mouse adrenocortical cells which express apolipoprotein E. , 1991, The Journal of biological chemistry.
[38] K. Weisgraber,et al. Human apolipoprotein E3 in aqueous solution. I. Evidence for two structural domains. , 1988, The Journal of biological chemistry.
[39] M. Pericak-Vance,et al. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[40] J. Haines,et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.
[41] R. Mahley,et al. Immunoregulatory plasma lipoproteins. Role of apoprotein E and apoprotein B. , 1980, The Journal of biological chemistry.
[42] C. Scriver,et al. The Metabolic and Molecular Bases of Inherited Disease, 8th Edition 2001 , 2001, Journal of Inherited Metabolic Disease.
[43] A. Lichtenstein,et al. Effects of ApoE genotype on ApoB-48 and ApoB-100 kinetics with stable isotopes in humans. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[44] R. Mahley,et al. Binding of arginine-rich (E) apoprotein after recombination with phospholipid vesicles to the low density lipoprotein receptors of fibroblasts. , 1979, The Journal of biological chemistry.
[45] D. Holtzman,et al. Nascent Astrocyte Particles Differ from Lipoproteins in CSF , 1998, Journal of neurochemistry.
[46] A. Roses,et al. Apolipoprotein E and Alzheimer's disease. , 1996, Annual review of neuroscience.
[47] K.,et al. Apoprotein E suppresses phytohemagglutinin-activated phospholipid turnover in peripheral blood mononuclear cells. , 1982, The Journal of biological chemistry.